Global X ETFs Genomics & Biotechnology UCITS ETF USD Acc (GNOG)
- Add to watchlist
- Create an alert
- This stock can be held in a
REPLICATION
SECURITIES LENDING
COUNTERPARTIES
Security | Weight |
---|---|
TAKARA BIO | 52.95% |
GENSCRIPT BIOTECH CORP | 11.69% |
10X GENOMICS INC | 2.86% |
NATERA INC | 1.94% |
SAREPTA THERAPEUTICS | 1.82% |
QIAGEN N.V. | 1.66% |
BIOMARIN PHARMACEUTICAL | 1.59% |
AGILENT TECHNOLOGIES INC | 1.57% |
BIO-TECHNE CORPORATION | 1.55% |
BIONTECH SE | 1.54% |
ASSET SPLIT
Annual & interim reports
Before you invest, please make sure you read the documents below
OBJECTIVE
Index: | The Global X Genomics & Biotechnology UCITS ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics v2 Index. |
---|---|
Aim: |
The Global X Genomics & Biotechnology UCITS ETF (GNOM LN) seeks to provide investment...
Read full aim for Global X ETFs |
Leverage: | 100% |
Currency hedging: | n/a |
COSTS
Ongoing Charge (OCF/TER): | 0.50% |
---|---|
Management fee: | 0.50% |
Indicative spread: | 0.7% |
In certain cases, where no TER or OCF is shown, additional costs may apply. Please ensure you have read the Key Investor Information Document, Factsheet, Prospectus and any other relevant documentation prior to investing.
Company announcements
No company announcements about Global X ETFs Genomics & Biotechnology UCITS ETF USD Acc were found.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.